Global Acute Intermittent Porphyria Treatment Market Size By Type (350mg, 313mg), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Acute Intermittent Porphyria (AIP) Treatment Market was valued at USD 425 million in 2023 and is projected to surpass USD 785 million by 2031, growing at a CAGR of 7.9% during the forecast period from 2023 to 2031. The market is witnessing significant momentum due to rising awareness of rare genetic disorders, the increasing availability of orphan drugs, and advancements in diagnostic methodologies. AIP is a rare metabolic condition caused by the deficiency of the enzyme porphobilinogen deaminase, leading to neurovisceral attacks. With early diagnosis and improved treatment options such as hemin infusions and emerging RNA-based therapies, the landscape for managing AIP is rapidly evolving.

Drivers

1. Growing Awareness and Diagnosis Rates

Increased awareness among healthcare professionals and improved genetic screening have led to earlier diagnosis of AIP, thereby enabling timely treatment and management. Awareness campaigns by healthcare organizations are also supporting patient identification and engagement.

2. Advancements in Therapeutic Options

Innovations such as RNA interference (RNAi)-based therapies, particularly givosiran, have revolutionized AIP treatment by offering long-term management and attack prevention. These breakthroughs are expanding the therapeutic landscape for chronic and acute cases.

3. Supportive Government Policies and Orphan Drug Designation

AIP treatments often receive orphan drug designation, enabling manufacturers to benefit from incentives such as tax credits, market exclusivity, and expedited regulatory processes. These policies have encouraged pharmaceutical companies to invest in the AIP treatment space.

Restraints

1. High Cost of Treatment

The cost of treating AIP—especially with RNA-based therapies and intravenous hemin—remains extremely high, which limits accessibility, particularly in low- and middle-income countries.

2. Limited Awareness in Developing Regions

Despite improvements, AIP remains underdiagnosed in several parts of the world due to a lack of specialist knowledge and diagnostic facilities, particularly in rural or low-income areas.

Opportunity

1. Expansion of RNA-Based Therapeutics

RNAi therapies like givosiran have shown strong efficacy in reducing AIP attacks. The continued development and commercialization of RNA-based drugs offer promising opportunities for long-term disease control and market growth.

2. Increasing Investments in Rare Disease Research

With the global rise in research funding for rare diseases, AIP has gained attention from biotechnology firms and academic institutions. This focus is leading to the discovery of novel therapeutic targets and improved formulations.

Market by Treatment Type Insights

The RNA Interference Therapy (RNAi) segment is projected to dominate the market during the forecast period. Givosiran (Givlaari), the first FDA-approved RNAi therapeutic for AIP, has shown a substantial reduction in annualized attack rates. Meanwhile, hemin-based therapies, such as Panhematin and Normosang, continue to serve as crucial options for managing acute attacks, especially in hospital settings.

Market by End-use Insights

Hospitals were the leading end-users in 2023, accounting for over 60% of total revenue. Hospitals provide intravenous administration of hemin during acute episodes, necessitating advanced care facilities. However, specialty clinics and homecare settings are projected to witness the fastest growth due to the shift toward chronic management and self-administered subcutaneous therapies like givosiran.

Market by Regional Insights

North America held the largest market share in 2023, driven by the presence of key players, high healthcare expenditure, and robust reimbursement frameworks for orphan drugs. Europe follows closely due to supportive regulatory frameworks and the presence of centers of excellence for rare diseases. Meanwhile, Asia-Pacific is expected to register the highest CAGR due to improved healthcare access, growing awareness, and favorable government initiatives.

Competitive Scenario

Key companies in the global AIP treatment market include:

Alnylam Pharmaceuticals, Inc.

Recordati Rare Diseases Inc.

Clinuvel Pharmaceuticals

Pfizer Inc.

Mitsubishi Tanabe Pharma Corporation

These players are focusing on expanding their presence through clinical trials, collaborations, and geographical expansion. For instance:

In 2023, Alnylam Pharmaceuticals reported extended real-world data on givosiran, showing sustained reduction in attack rates and improved patient-reported outcomes.

Recordati announced in 2024 the expansion of Normosang availability in emerging markets to improve access.

Scope of Work – Global Acute Intermittent Porphyria Treatment Market

Key Market Developments

2023: Alnylam Pharmaceuticals received additional regulatory approvals for givosiran in South America and Asia-Pacific.

2024: Clinuvel Pharmaceuticals initiated a phase II trial for a new peptide-based therapy aimed at reducing attack severity in AIP patients.

2025: Mitsubishi Tanabe Pharma entered a licensing agreement to co-develop a novel siRNA candidate for porphyria with a biotech startup in Japan.

FAQs

1) What is the current market size of the Global Acute Intermittent Porphyria Treatment Market?

The market was valued at USD 425 million in 2023.

2) What is the major growth driver of the Global Acute Intermittent Porphyria Treatment Market?

The adoption of RNA-based therapeutics like givosiran is a major growth driver.

3) Which is the largest region during the forecast period in the Global Acute Intermittent Porphyria Treatment Market?

North America is the largest region, supported by high awareness and healthcare infrastructure.

4) Which segment accounted for the largest market share in the Global Acute Intermittent Porphyria Treatment Market?

The RNA Interference Therapy segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Acute Intermittent Porphyria Treatment Market?

Key players include Alnylam Pharmaceuticals, Recordati Rare Diseases, Clinuvel Pharmaceuticals, and Mitsubishi Tanabe Pharma.